BRCA1 and neoplasm: Even among HGSC patients with BRCA1-heterozygous tumors that are supersensitive to DNA-damaging drugs and poly (ADP-ribose) polymerase (PARP) inhibitors, the utility of NACT is observed to facilitate the expansion of pre-existing BRCA1-proficient tumor clones 26.